Management ChangeAug 6, 2026, 05:36 PM
Tango Therapeutics Executive Chair Dr. Barbara Weber Departs
AI Summary
Tango Therapeutics announced that Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, leading to her resignation from all officer and board positions. Her departure was not due to any disagreement with the company. In connection with her separation, Dr. Weber was offered a severance package including base salary through December 31, 2026, COBRA reimbursement, accelerated vesting of stock awards, and a pro-rata annual incentive.
Key Highlights
- Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026.
- She resigned from all officer and board member positions, including the Board of Directors.
- Her resignation was not a result of any disagreement with the company.
- Severance pay at current base salary through December 31, 2026.
- Reimbursement for COBRA premiums up to December 31, 2026.
- Acceleration of vesting for stock options and restricted stock units for an additional 12 months.
- Extended exercise period for vested stock options until August 3, 2027, or original expiration.
- Pro-rata annual incentive compensation for 2026, payable by March 15, 2027.
Price Impact
More from TNGX